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Abstract: Vaccination is one of the most valuable
weapons against infectious diseases and has led to a
significant reduction in mortality and morbidity. However,
for most viral hemorrhagic fevers caused by arenaviruses,
no prophylactic vaccine is available. This is particularly
problematic as these diseases are notoriously difficult to
diagnose and treat. Lassa fever is globally the most
important of the fevers caused by arenaviruses, poten-
tially affecting millions of people living in endemic areas,
particularly in Nigeria. Annually, an estimated 300,000
humans are infected and several thousands succumb to
the disease. The successful development of the vaccine
‘‘Candid#1’’ against Junin virus, the causative agent of
Argentine hemorrhagic fever, proved that an effective
arenavirus vaccine can be developed. Although several
promising studies toward the development of a Lassa
fever vaccine have been published, no vaccine candidate
has been tested in human volunteers or patients. This
review summarizes the immunology and other aspects of
existing experimental arenavirus vaccine studies, discuss-
es the reasons for the lack of a vaccine, and proposes a
plan for overcoming the final hurdles toward clinical trials.
Literature Search
The literature search was based on PubMed, Embase, and Web
of Science. The initial search term used was ‘‘Lassa OR Junin OR
Machupo OR Guanarito OR Sabia AND (vaccine OR vaccina-
tion).’’
Titles and abstracts were screened to exclude irrelevant
publications.
Introduction
The family Arenaviridae contains four important species that
cause severe hemorrhagic zoonoses in humans. Together, they
have an important impact on public health in endemic regions
(Figure 1). Lassa virus (LASV) is endemic to Africa. The other
three species (Machupo, Junin, and Guanarito viruses [MACV,
JUNV, and GTOV, respectively]) are from South America [1].
The prototypic arenavirus is lymphocytic choriomeningitis virus
(LCMV), which can also cause disease in humans, especially in
immunocompromised patients [2].
Arenaviruses carry two RNA genome segments (small, S, and
large, L), which encode two genes each [3]. The S-segment
encodes the glycoprotein precursor (GPC) and, in ambisense, the
nucleoprotein (NP). Similarly, the L-segment encodes the matrix
protein Z and, in negative sense, the multifunctional protein L [4].
Natural reservoirs include different species of rodents, depend-
ing on the arenavirus [5]. The exact mode of transmission to
humans is unknown but probably occurs through direct contact
with the infected host or food contaminated with excrement.
Direct human-to-human transmission is possible and regularly
occurs in clinical settings in endemic areas [6].
Little is known about the pathogenesis of the diseases caused by
arenaviruses. A putative explanation for the severe symptoms is an
immunopathology caused by an imbalanced host–pathogen
interaction with a perpetuated excessive reaction of host immune
cells combined with delayed viral clearance [7]. Furthermore,
early immune evasion may participate in the disease through
delayed virus clearance [8].
Treatment options for the patients are limited. In addition to
intensive care, the broad-band antiviral drug ribavirin has proven
to be effective if administered early in the course of the disease
(before day 6) [9]. The caveat is the need for early diagnosis, and
this is a genuine problem, since infections with arenaviruses are
initially often mistaken for malaria, typhoid fever, or other
common tropical diseases due to the nonspecific nature of the
symptoms [10,11].
The only currently available vaccine is Candid #1. This
attenuated JUNV strain was generated through multiple passaging
and provided good protection in clinical trials against argentine
hemorrhagic fever (AHF) with an excellent safety profile [12]. The
historical development and biological properties of this vaccine
were recently reviewed in a concise overview [13].
Although there has been much effort to develop vaccines against
LASV, none have been effective enough to warrant clinical trials.
In this review, we summarize the work that has been done toward
the development of vaccines against hemorrhagic fever caused by
arenaviruses and discuss the current obstacles toward a licensed
vaccine.
Immunological Basis
Neutralizing Antibodies
The role of neutralizing antibodies (nAbs) in the control of
arenavirus infections is controversial, but has been studied for
LASV and JUNV in both human patients and animal models. The
use of convalescent plasma has also been studied. Monkeys and
guinea pigs are protected against Lassa fever by treatment with
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plasma from convalescent animals containing high titers of nAb
[14,15]. To be protective, however, the plasma had to be
administered directly after infection. Treatment after the onset
of symptoms was not beneficial. The time point for successful
application could be delayed by using a combination of plasma
and ribavirin in experimental settings [16], but the treatment of
Lassa fever patients with plasma of survivors did not confer
protection [9]. The treatment of these patients with convalescent
plasma was initiated within 24 h after admission to hospital. The
patients were subdivided into two groups. One group was treated
before day 6 after onset of symptoms and the second group after 6
days of disease. No beneficial effects were observed in either
group.
In a placebo-controlled treatment study of JUNV, however,
convalescent plasma of human AHF survivors benefited AHF
patients with acute disease [17]. Similarly to the above-mentioned
LASV study, treatment was initiated only after onset of symptoms.
In contrast to the case of LASV, however, mortality caused by
JUNV was reduced if treatment began within 8 days of onset of
symptoms. The difference in efficacy for LASV versus JUNV
infections therefore seems unrelated to the time at which treatment
was initiated. The divergence in study outcomes could be
explained by the presence (JUNV) or absence (LASV) of nAbs
in convalescent serum. However, the serum was not assayed for
neutralizing antibodies.
The role of nAbs during vaccination and natural infection has
also been investigated.
Heterologous vaccination with an apathogenic, related virus has
been tested for two pairs: LASV/Mopeia virus (MOPV) and
JUNV/Tacaribe virus (TACV). Cross-protection was demonstrat-
ed for LASV/MOPV without the appearance of nAbs [18].
In the case of JUNV/TACV, two groups [19,20] showed that
TACV infection leads to heterologous protection of guinea pigs
against JUNV challenge. However, the first group could not detect
substantial amounts of heterologously cross-reacting and neutral-
izing antibodies after a single vaccination. In a later study, JUNV
cross-neutralizing antibodies were detected 65 days after immu-
nization with TACV in guinea pigs [21].
Experiments in marmosets confirmed cross-protection between
TACV and JUNV [22]. After vaccination and before JUNV
challenge, no cross-reactive nAbs were detectable in TACV-
immunized nonhuman primates. Homologous nAbs could only
be measured after infection with JUNV. The authors concluded
that cellular immunity may play an important role in protection.
Furthermore, in another study, guinea pigs were not protected
against the lethal XJ strain after vaccination with formalin-
treated JUNV, despite the detection of nAbs before challenge
[23]. Finally, Lopez and colleagues [24] measured nAbs after
immunization with recombinant vaccinia virus expressing either
TACV or JUNV GP, but the role of the nAbs in protection
against a lethal JUNV challenge in guinea pigs was unclear. In
summary, nAbs can prevent infection and play a role in
arenavirus clearance, at least for JUNV infections. Nevertheless,
the absence of nAbs in animals that were protected does suggest
that cellular immunity is important for protection against both
JUNV and LASV infections.
T-Cell Epitopes
Knowledge of protective T-cell epitopes is essential for the
development of vaccines based on cellular immunity.
Ter Meulen and colleagues screened for T-cell clones in Lassa
fever survivors using recombinant antigen [25] and identified five
Figure 1. Endemic regions for the pathogenic arenaviruses mentioned in the text. The color intensity indicates the population density.
Lassa virus is clearly endemic in the most populated region of Africa; a vaccine is therefore of high relevance for public health. The map is available
under a Creative Commons license (http://www.flickr.com/photos/54545503@N04/5485517485/sizes/o/in/photostream/).
doi:10.1371/journal.ppat.1003212.g001
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Human Leukocyte Antigen DR-1 (HLA-DR)–restricted epitopes
in the nucleoprotein of LASV (aa 176–188, 190–202, 288–300,
379–391, and 498–510) that could induce the proliferation of
peripheral blood mononuclear cells (PBMCs) from donors in
vitro. Proliferating cells were CD4+. The authors also checked for
cross-reactivity with homologous epitopes from MOPV and a
Nigerian LASV strain. They found partial cross-reaction of T-
cells from two of three tested donors. In another study, based on
computational epitope predictions, MHC I (HLA-A02) LASV NP
and GPC immunogenic peptides were identified [26]. Some of
these predicted epitopes could be used to elicit a CD8+ response
in HLA-A02 transgenic mice. Botten and colleagues designed a
study system using HLA-A02 transgenic mice and challenged
peptide-immunized animals with rVaccinia virus expressing
LASV GP or NP. This elegant method allowed in vivo screening
outside of a BSL-4 setting not only for immunogenic but also for
protective T-cell epitopes. However, it remains a limitation that
the challenge was performed with a virus from another family
expressing LASV antigens rather than LASV itself [27]. The
authors identified highly protective epitopes that were conserved
among different LASV strains. The crucial question, however, is
whether there are epitopes in humans allowing reliable cross-
protection between virus strains or even species. The question of
cross-reactivity is important, as the sequence variability of
arenaviruses in general, and of LASV in particular, is very high.
Insufficient cross-protection could in the worst case lead to a
reduced immune response due to original antigenic sin [28]. One
epitope in LASV GPC (403–417) was found that elicited cross-
protective CD4+ cells against LCMV in C3H/HeJ (H-2k) mice
[29]. Also, Oldstone et al. (2001) found that the H-2d restricted
epitope NP 118–126 of LCMV induces cross-protection to other
Old World arenavirus homologues but not to the New World
homologue [30].
A human T-cell epitope identified at position 289–301 in LASV
GPC is highly conserved within Old and New World arenaviruses.
CD4+ T-cells from a Lassa fever reconvalescent donor reacted to
this epitope when the sequences were changed to the homologue
sequences of other arenaviruses [31].
In another study, HLA-A02 and HLA-A03 restricted, protective
epitopes were identified for different arenaviral pathogens [32].
The authors proved the feasibility of inducing a multivalent T-cell
response by using a cocktail of epitopes from different arenavirus
species to create broad protection. They also addressed the
question of the distribution of MHC haplotypes in different ethnic
populations and calculated the population coverage. This was
done based on allele frequency and binding affinity data. Later,
the study was extended to focus on single epitopes rather than
mixing species-specific epitopes that protect across species borders
[33].
In Tables 1 and 2, we summarize the known epitopes for CD8
and CD4, respectively. None of the mentioned studies demon-
strated an increased severity of pathology, as would be expected in
the case of incomplete protection. However, the current data do
not allow a clear prediction of whether a T-cell–based vaccine will
increase the risk of immunopathology in clinical trials. In the case
of LCMV Armstrong Cl13, which establishes a persistent infection
in mice, the number of specific T-cells at the time of infection can
determine different disease outcomes. The presence of a low
amount of specific T-cells resulted in persistence, whereas a
medium amount of specific T-cells led to immunopathology.
Complete virus clearance was seen only in the presence of a high
number of T-cells [34]. Based on this dataset, a mathematical
model for protection, T-cell pathology, and viral persistence was
created [35].
Experimental Vaccines for JUNV and LASV
The most relevant vaccine trials are summarized in Table 3.
Junin Virus Candid #1 (C#1)
A successful example of a live vaccine for an arenavirus is JUNV
Candid#1 (C#1), which confers reliable and safe protection
against severe AHF. It is licensed in Argentina for the vaccination
of people living in high-risk areas. A recent review summarizes the
historical development and biological properties of the vaccine
[13]. Using recombinant viruses, a single amino acid in the
transmembrane domain of the GPC was found to be responsible
for the attenuated phenotype of C#1. A change from phenylal-
anine to isoleucine on position 427 of GPC (F427I) attenuated the
phenotype in mice and led to increased survival upon challenge
[36]. Until now, no mechanistic explanation for the attenuation
has been found.
Table 1. Human HLA class I restricted epitopes against
pathogenic arenaviruses.
Epitope
Peptide
Sequence
MHC I
Restriction Reference(s)
GTOV
GPC427–435 GTTSLFLHL HLA-A2 [33]
L1977–1985 ATVKNVVLR HLA-A*1101 [32]
JUNV
GPC18–26 ALNIALVAV HLA-A*0201 [32]
LASV
GPC42–50 GLVGLVTFL HLA-A*0201 [27]
GPC60–68 SLYKGVYEL HLA-A*0201 [26,27]
GPC111–120 SIINHKFCNL HLA-A*0201 [32]
GPC441–449 YLISIFLHL HLA-A*0201 [26,27]
LCMV
GPC10–18 ALPHIIDEV HLA-A*0201 [76,77]
GPC11–19 LPHIIDEVI B*4402 [77]
GPC38–46 FATCGIFAL B*0702 [77]
GPC46–55 LVSFLLLAGR HLA-A*1101 [32]
GPC112–120 FTNDSIISH HLA-A*1101 [32]
GPC447–455 YLVSIFLHL HLA-A*0201,
B*1501
[76,77]
NP45–53 SEVSNVQRI B*4402 [77]
NP69–77 SLNQTVHSL HLA-A*0201 [76,77]
NP246–254 AAVKAGAAL B*0702 [77]
NP414–422 KQFKQDSKY B*1501 [77]
Z24–33 TTYLGPLSCK HLA-A*1101 [32]
Z49–58 YLCRHCLNLL HLA-A*0201 [32,76,77]
MACV
GPC18–26 ALNIALVAV HLA-A*0201 [32]
GPC444–452 [33]
NP19–27 GLSQFTHTV HLA-A*0201 [32]
NP82–90 SIQKNTIFK HLA-A*1101 [32]
NP432–440 AMPGVLSYV HLA-A*0201 [32]
Z27–36 RTAPPSLYGR HLA-A*1101 [32]
Italics, predicted restriction only. GTOV, Guanarito virus; JUNV, Junin virus; LASV,
Lassa virus; LCMV, lymphocytic choriomeningitis virus; MACV, Machupo virus.
doi:10.1371/journal.ppat.1003212.t001
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Apathogenic Arenaviruses as Live Vaccines
The use of live-attenuated strains or related apathogenic
viruses for vaccination has a long history, starting with vaccinia
virus for the prevention of smallpox or the yellow fever virus 17D
strain [37,38]. Both elicit a powerful response of neutralizing
antibodies against the agent but also effectively target cellular
adaptive immunity [39]. The greatest advantage of live vaccines
is the complete activation of several immune pathways, which is
analogous to what happens during natural infection. Initial
animal experiments suggested that the use of genetically close
apathogenic arenavirus species for vaccination against AHF and
Lassa fever could be effective. Beginning in the 1970s, the first
successful LASV vaccination experiments were done with MOPV
in rhesus monkeys [18,40]. The animals showed no signs of
disease after MOPV infection and survived an otherwise fatal
infection with LASV. Previously, similar experiments had been
conducted with TACV and JUNV in guinea pigs [20].
Unfortunately, very little is known about the infection of humans
with MOPV and TACV. It is unclear whether the infection of
humans with these viruses is truly apathogenic, as some of the
monkeys infected with MOPV showed pathological alterations of
the liver and kidney [41]. It will be important to prove the safety
of apathogenic arenaviruses in humans before vaccine candidates
can be tested for efficacy.
Reassortment of LASV and MOPV
An interesting live-attenuated vaccine candidate is the chimeric
virus ML-29. Lukashevich generated a recombinant virus carrying
the LASV S-segment and the MOPV L-segment by co-infection of
Vero cells with both virus species [42]. The use of a plaque-
purified clone (ML29) as a vaccine against LASV showed
promising results [43]. While MOPV vaccination was also
protective, only ML29 vaccinated animals did not show a transient
elevation of liver enzymes in plasma after LASV challenge.
Immunity was conferred through cellular responses while the
humoral response was negligible (nAb titer,1:20). In this and a
following study, the recombinant ML29 proved safe in nonhuman
primates [44]. The attenuated phenotype is attributed to the
presence of the L-segment of MOPV in the recombinant, as no
other differences in sequence were detected with respect to
corresponding wild-type strains [45].
Table 2. Human HLA class II restricted epitopes against
pathogenic arenaviruses.
Epitope Peptide Sequence
MHC II
Restriction Reference(s)
LASV
GPC236–250 PSPIGYLGLLSQRTR HLA-DRB1*0101 [78]
GPC241–255 YLGLLSQRTRDIYIS HLA-DRB1*0101 [78]
GPC282–294 RWMLIEAELKCFG HLA-DRB [31]
GPC289–301 ELKCFGNTAVAKC HLA-DRB [31]
GPC394–406 LNETHFSDDIEQQ HLA-DRB [31]
GPC476–490 SCGLYKQPGVPVRWK HLA-DRB1*0101 [78]
NP176–188 FGTMPSLTLACLT HLA-DRB [79]
NP190–202 QGQVDLNDAVQAL HLA-DRB [79]
NP288–300 ALGMFISDTPGER HLA-DRB [79]
NP379–391 QLDPNAKTWMDIE HLA-DRB [79]
NP498–510 VWDQYKDLCHMHT HLA-DRB [79]
GTOV
GPC131–145 KGSPEFDWILGWTIK HLA-DRB1*0101 [78]
L181–195 DQEYHRLIHSLSKTS HLA-DRB1*0101 [78]
L391–405 RVLDILVARRLLLKK HLA-DRB1*0101 [78]
L1826–1840 IQLVFSSMINPLVIT HLA-DRB1*0101 [78]
NP166–180 KLNNQFGSMPALTIA HLA-DRB1*0101 [78]
NP191–205 NNVVQALTSLGLLYT HLA-DRB1*0101 [78]
NP236–250 ISGYNFSLSAAVKAG HLA-DRB1*0101 [78]
NP541–555 IPIQLLPNTLVFQAK HLA-DRB1*0101 [78]
JUNV
GPC46–60 FFVFLALAGRSCTEE HLA-DRB1*0101 [78]
L381–395 VGQMLMLVNDRLLDI HLA-DRB1*0101 [78]
L391–405 RLLDILEAIKLIRKK HLA-DRB1*0101 [78]
L411–425 KWVQMCSRTLKNSHQ HLA-DRB1*0101 [78]
L1491–1505 MFIRNCARKVFNDIK HLA-DRB1*0101 [78]
L1711–1725 NKNFFWAVKPKAVRQ HLA-DRB1*0101 [78]
LCMV
GPC66–80 DIYKGVYQFKSVEFD *0701 [77]
GPC71–85 VYQFKSVEFDMSHLN *0701 [77]
GPC341–355 HLFKTTVNSLISDQL *0701 [77]
GPC421–435 LRKDYIKRQGSTPLA HLA-DRB1*0101 [78]
L256–270 RNFQKVNPEGLIKEF HLA-DRB1*0101 [78]
L946–960 HLRKVILSEISFHLV HLA-DRB1*0101 [78]
NP6–20 EVKSFQWTQALRREL HLA-DRB1*0101 [78]
NP86–100 KNVLKVGRLSAEELM *1101 [77]
NP106–120 LEKLKAKIMRSERPQ *0801 [77]
NP236–250 NISGYNFSLGAAVKA *0701 [77]
NP261–275 LESILIKPSNSEDLL *0701 [77]
NP281–295 AKRKLNMFVSDQVGD *0701 [77]
NP311–325 EGWPYIACRTSIVGR *0701 [77]
NP356–370 VGLSYSQTMLLKDLM *0701 [77]
NP411–425 VDQKQFKQDSKYSHG *0701 [77]
NP521–535 MDCIIFESASKARLP HLA-DRB1*0101,
*0801
[77,78]
MACV
GPC96–110 NSFYYMKGGVNTFLI HLA-DRB1*0101 [78]
Table 2. Cont.
Epitope Peptide Sequence
MHC II
Restriction Reference(s)
GPC251–265 SKTHLNFERSLKAFF HLA-DRB1*0101 [78]
GPC446–460 ASLFLHLVGIPTHRH HLA-DRB1*0101 [78]
L391–405 DRVLDILEAVKLIRK HLA-DRB1*0101 [78]
L636–650 RYFLMAFANQIHHID HLA-DRB1*0101 [78]
L866–880 DYLILKNLTGLVSAG HLA-DRB1*0101 [78]
L1491–1505 TSFIRNCARKVFNDI HLA-DRB1*0101 [78]
L1711–1725 NNQNFFWAVKPKVVR HLA-DRB1*0101 [78]
NP191–205 NSVVQALTSLGLLYT HLA-DRB1*0101 [78]
Z21–35 PSAEFRRTAPPSLYG HLA-DRB1*0101 [78]
Italics, predicted restriction only. GTOV, Guanarito virus; JUNV, Junin virus; LASV,
Lassa virus; LCMV, lymphocytic choriomeningitis virus; MACV, Machupo virus.
doi:10.1371/journal.ppat.1003212.t002
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Inactivated or Dead Vaccines
Virus-like particles containing GP1, GP2, NP, and Z [46] were
produced after transient transfection of expression plasmids into
HEK-293T cells. Binding antibodies as determined by ELISA
were induced. The protectiveness of the vaccine, and whether or
not these antibodies were neutralizing, was not investigated.
Further functional experiments will be necessary to predict
whether or not this approach will be successful.
Gamma-irradiated LASV did not protect rhesus macaques
against challenge, despite an increase in anti-LASV antibodies.
This was attributed to the lack of adequate cellular immunity [47].
Guinea pigs vaccinated with formalin-inactivated Junin virus
produced neutralizing antibodies but were not protected upon
challenge [23]. These studies indicate that a certain level of
antigen expression is mandatory to elicit immunity and that
cellular immunity may be responsible for clearance of the virus.
In contrast to these findings, Amanna et al. recently reported a
LCMV vaccine based on purified LCMV particles inactivated by
3% H2O2. The vaccine induced T-cell responses when high
concentrations (50 mg) of inactivated virus were used in mice [48].
Mucosal Vaccination
An attractive way to deliver antigen for vaccination is oral
uptake. In many instances, the mucosa is the first part of the host
to come into contact with a pathogen. Oral application is
furthermore minimally invasive and vaccination campaigns can
be performed with less effort. S. typhimurium and vaccinia virus
were genetically modified to express LASV NP and LCMV NP.
Mice inoculated with a recombinant vector showed LASV NP–
specific IgA and specifically reactive splenocytes [49]. Challenge
experiments involving intracerebral LCMV infection after intra-
gastric immunization with vectors expressing LASV antigen
protected only approximately one third of the LCMV-challenged
animals [50]. The authors concluded that this was due to the use
of a heterologous antigen (LASV antigen against LCMV
challenge) because intragastric infection of mice with vector
expressing LCMV NP before intracerebral challenge led to 100%
survival of the animals in the same setting. The idea of intragastric
immunization is particularly attractive when immunization
campaigns in wild animals are considered (Mastomys natalensis);
vaccination could be accomplished in a manner similar to that of
rabies vaccination in foxes [51].
Recombinant Viruses Expressing Arenavirus Proteins
Recombinant virus vectors have been in use since the early
1980s [52,53]. Their use as vaccine vectors for the expression of
foreign antigens is a valuable tool and has several advantages
compared with other vaccine platforms.
The biggest advantage is the use of genetically defined material.
The antigen can be optimized to elicit the desired immune
response. Safety aspects, such as the production of replication-
incompetent viruses, are more easily addressed [54]. There is no
Table 3. Summary of selected animal JUNV and LASV vaccine trials.
Vaccine Antigen
Challenge
Virus Protection
Animal Models
Tested Safety Reference(s)
Candid#1 All homologous JUNV Full Already in use
in humans
Safe in humans Reviewed in [13]
ML-29 NP/GPC (LASV); L/Z
(MOPV)
LASV Full Guinea pig, nonhuman
primates, mouse
Safe in primates [43,44]
MOPV All (MOPV) LASV Full Nonhuman primates Safe in primates [18,40,41]
TACV All (TACV) JUNV Full Nonhuman primates,
guinea pig
Safe in primates [20,21,22]
rVaccinia virus NP (LASV) LASV Full Guinea pig Vector is safe1 [57]
rVaccinia virus NP (LASV) LASV None Nonhuman primates Vector is safe1 [59]
rVaccinia virus GPC (LASV) LASV Partial (86%) Nonhuman primates Vector is safe1 [59]
rVaccinia virus GPC (LASV) JUNV Partial (72%) Guinea pig Vector is safe1 [24]
rYellow fever virus 17d GP1+GP2 (LASV) LASV Partial (83%) Guinea pig Vector is safe2 [64]
rVesicular stomatitis virus GPC (LASV) LASV Full, transient
viremia
Nonhuman primates,
single human
application
Safe in primates [60,61]
rVenezuelan equine
encephalitis virus
GPC+NP (LASV) LASV Full, very low
viremia
Guinea pig Safe in primates [66]
rSalmonella typhimurium NP (LASV) LCMV3 Partial (33%) Mouse Vector is safe4 [50]
rSalmonella typhimurium NP (LCMV) LCMV3 Full Mouse Vector is safe4 [50]
LASV VLPs All (LASV) LASV Not tested Mouse nd (not infectious) [46]
a˜-irradiated virus All (LASV) LASV None Nonhuman primates Safe in primates [47]
Formalin-treated virus All (JUNV) JUNV None Guinea pig Safe in Guinea pigs [23]
DNA vaccine NP (LCMV) LCMV3 Titer reduction Mouse Nd (not infectious) [69]
1Vaccinia virus has been used for human application.
2Yellow fever virus 17D has been used for human application.
3Virus used for challenge. Aim of the study was to explore the use of this method for vaccination against LASV infection.
4Safety tests for attenuated Salmonella typhimurium expressing hepatitis B virus antigens have been done in human volunteers. JUNV, Junin virus; LASV, Lassa virus;
LCMV, lymphocytic choriomeningitis virus; MOPV, Mopeia virus; TACV, Tacaribe virus.
doi:10.1371/journal.ppat.1003212.t003
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need to rely on the random mutations required for the generation
of attenuated WT strains.
The different virus platforms allow the selection of a vector that
has a similar tropism to that of the target virus (e.g., recombinant
vaccinia virus for intradermal vaccination or recombinant
influenza virus for targeting the respiratory tract mucosa [55,56]).
For arenavirus, different recombinant virus platforms have been
tested. Vaccinia virus (VV) vectors have been modified to express
LASV NP [57] and GPC [58]. Both antigens protected guinea
pigs against a lethal challenge with LASV. Similar experiments
have been performed for JUNV [24], but the guinea pigs
vaccinated with recombinant VV expressing JUNV-GP were not
fully protected (72% survival) and protection after vaccinations
with TACV antigens (GPC and NP) had even poorer outcomes
(50% and 0% protection, respectively). Interestingly, neutralizing
antibodies again seemed to play no obvious role in the protected
animals. In a series of experiments in nonhuman primates, the
roles of different LASV antigens were tested. Vaccinia virus
vectors expressing only the N-terminal (GP1) or the C-terminal
(GP2) part of GPC or the NP were produced. Animals that
received a vector expressing only GP1 or GP2 succumbed to
disease upon challenge. Similarly, vaccination with the NP-only
vector did not confer significant protection. Only when the whole
glycoprotein or both parts were used for immunization were
animals significantly protected against challenge [59]. The
experiments were performed using rhesus and cynomolgus
macaques with comparable results. The authors concluded that
similar observations could be expected in humans.
In 2004, the construction of a recombinant vesicular stomatitis
virus (rVSV) carrying LASV glycoprotein was described [60]. The
growth of the virus with the foreign GP was attenuated in mice
compared with the wild-type vector. In challenge experiments in
nonhuman primates, the vector protected animals against lethal
LASV infection. However, the protection was not sterile and
LASV viremia could be measured on day 7 postinfection. The
viremia at that time point was comparable to that of control
animals that received an irrelevant immunization. Nevertheless,
vaccinated animals showed no signs of disease and clearance of the
virus shortly afterwards [61]. The rVSV vaccine backbone has
already been used in one human case of accidental Ebola
exposure. The patient showed a transient elevation of body
temperature, and vaccine vector RNA was detected by PCR in the
blood. No other severe side effects were observed. Together with
data available from monkey experiments, the safety of the vector
seems to be good [62].
The attenuated yellow fever strain 17D (YFV 17D) is one of the
oldest and most successful virus vaccines ever used. Use of
recombinant YFV 17D is therefore promising because its safety
and potential to elicit immunity are known. The addition of
foreign genes to the YFV genome further attenuates the
replication capacity of the virus. Some recombinant YFV 17D-
based vaccines are already in clinical trials. A general review of
YFV 17D vectors has been published recently [63]. Two studies
described the use of YFV 17D–expressing LASV GP or GP1 and
GP2 for vaccination of guinea pigs [64,65]. While the overall
survival was 80% all animals showed viremia and developed
disease. Furthermore, the use of a vaccine backbone with a known
safety profile would significantly facilitate its use in a clinical trial.
Another vaccine vector that proved effective in guinea pigs
against LASV challenge is a Venezuelan equine encephalitis virus
(rVEE) replicon particle expressing GP or NP [66]. Animals were
fully protected against LASV challenge after prime/boost/boost
immunization with this vector. A recombinant LCMV expressing
LASV antigens has recently been described [67]. The use of
modified apathogenic arenaviruses could be another option for the
development of vaccines against pathogenic relatives of arenavi-
ruses.
DNA Vaccine
Plasmid DNA can be used to express and deliver target genes
into the host to induce immunity. Antigen-presenting cells and
other body cells take up plasmid DNA and the ensuing protein
synthesis from the plasmid DNA leads to MHC I and II
presentation of peptides encoded by the plasmid DNA [68].
Whitton et al. have extended their extensive work on LCMV to
the highly pathogenic LASV [69]. After injecting plasmid DNA
encoding LASV or LCMV NP into mice, they measured the
immune response and protective potential upon challenge with
LCMV or Pichinde virus (PICV). LCMV virus titers were lower in
vaccinated than in naı¨ve animals after challenge, irrespective of
which antigen was used. This indicates cross-species protection.
Even PICV titers were lower after LCMV and LASV NP
immunization.
Although DNA vaccines have an excellent safety profile in
humans, their rather weak immunogenicity may require prime-
boost vaccination with other vectors.
Conclusion and Discussion
The development of vaccines against arenaviruses started
shortly after the identification of JUNV as the causative agent of
AHF in the 1950s. These efforts culminated in the introduction of
the licensed Candid#1 vaccine in the 1990s, which led to a
significant decrease in mortality and morbidity to AHF [12].
We will focus on LASV in the Discussion because it is by far the
most important pathogenic arenavirus clinically and has an
important impact on public health. Approximately 100,000 to
300,000 cases including several thousand fatal outcomes are
estimated to occur annually in West Africa [70]. Much effort has
been put into the development and preclinical testing of LASV
vaccines, as revealed by the number of publications on this topic.
Many different vaccine vectors and platforms have been evaluated
for use as a LASV vaccine (Table 3). We therefore raise the
question of why not a single vaccine system has entered a clinical
trial. We discuss the hurdles clinicians face in treating these
diseases and how these hurdles could be surmounted.
Firstly, LASV is a neglected tropical disease. Affected countries
are Nigeria, Ivory Coast, Mali, Guinea, Sierra Leone, and Liberia.
The specific socioeconomic problems related to LASV vaccination
are probably the biggest hurdles to be crossed. People who are at
the highest risk of infection are also the poorest in the above-
mentioned endemic countries. Poor hygiene and sanitation in
these countries increases the probability of LASV exposure.
Furthermore, many people living in these countries are unable to
pay for vaccination. Prime-boost vaccination campaigns are
difficult to organize due to the poor infrastructure. The low
commercial value of a LASV vaccine makes the development of
such vaccines an unattractive prospect for pharmaceutical
companies. Instead, international nongovernmental organizations
(e.g., WHO and the World Bank) and foundations must provide
the necessary financial support. Governments of the endemic
countries should also contribute by logistically supporting clinical
investigations in LASV patients and helping to organize phase II
clinical trials for vaccine studies after phase I safety trials have
been conducted in Western countries. As Nigeria is the biggest
local economic power and among the top 10 oil-producing
countries worldwide, it could take a substantial lead in these
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actions (World Bank, GDP ranking 2011 [71]; OPEC market
indicators, December 2012 [72]).
Secondly, the mechanisms underlying protection are still
unclear. It seems to be the consensus that nAbs play no major
role in the clearance of LASV. The specific role of T-cells in
LASV infections, however, remains speculative [73]. In humans,
only a few studies investigating the role of T-cells in Lassa fever
outcome exist. The efficacy of cross-protection between different
LASV strains by a single vaccine or a mixture remains to be
determined.
Even for JUNV, no complete picture of the mechanisms that
underlie protection through vaccination is available. nAbs are
often seen as a correlate of protection against disease. The role of
T-cells has not been studied in much detail and the role of nAbs in
JUNV infections may have been overestimated. Therefore, we
hypothesize that the contribution of T-cells to virus clearance is
stronger than currently assumed. The many studies showing
protection through vaccination without detectable nAb titers
before infection support a stronger role for T-cells than previously
thought. In our opinion, there is a need for the development of
simple ‘‘bed-side’’ T-cell assays to study the role of T-cells. One
could imagine assays similar to the interferon-c release assay for
tuberculosis [74]. With simple T-cell assays like this, T-cell
presence in vaccinated persons and patients could be determined.
It would be interesting to see how this would correlate with
protection and recovery, and compare with the protection and
recovery provided by the antibody response.
Thirdly, it is still unknown what role T-cells play in arenavirus
pathogenesis. T-cell–mediated pathology is a mechanism that
could possibly play a role in the development of severe arenaviral
disease. We recently showed that T-cells play a major role in
causing immunopathology in a mouse model for LF using mice
transgenic for HLA-A02 [7]. Until now, it has been unclear
whether vaccine-related T-cell pathology can occur following
imperfect vaccination. If it does, it could have adverse conse-
quences for clinical trials of these vaccines in humans.
Fourthly, the safety aspects of vaccination campaigns have to be
considered. Besides the more general safety concerns linked to
vaccination, the issue of HIV co-infection is of high importance.
LASV-endemic regions are also regions with a high HIV
prevalence rate. There are no data available on Lassa fever in
relation to HIV. The safety of vaccination with live-attenuated
vaccines in immunocompromised individuals is unclear. A recent
meta-analysis on the use of the yellow fever vaccine YF17D in
immunocompromised patients [75] did not show a high risk of
severe adverse effects in HIV-infected individuals. Nevertheless,
the test groups were quite small and more information will be
needed to draw firm conclusions about safety.
We propose the following steps to move closer to clinical trials of
LASV vaccines: (i) Studies of the role of T-cells during
pathogenesis (especially for LASV); (ii) identification of the
correlate of protection in survivors; and (iii) identification of the
most promising vaccine concept (in terms of safety, protective
efficacy, and technical feasibility). The scientific community should
meet in an international conference on LASV vaccines and discuss
the different approaches.
In our opinion, the experimental basis is at a sufficient stage of
advancement for clinical trials to proceed. Much work done in
different animal species (including nonhuman primates) has
demonstrated the safety and efficacy of several vector systems for
vaccination against LASV infection.
What will be the most promising vector system for clinical trials?
MOPV in humans will probably offer the most effective protection
against subsequent LASV infection, but the risks involved in using
a nonattenuated BSL-3 agent (BSL-2 in Europe) in clinical trials
are currently too high. The same is true for the recombinant
MOPV-LASV assortant ML-29. DNA vaccination would be
cheap and safe, but it is highly questionable whether a single
application would be sufficient for protection. As inactivated virus
particles seem to be ineffective, we think that the most promising
vaccine will probably be a system based on recombinant virus
vectors (e.g., vaccinia virus or yellow fever virus) for which safety
data (especially as mentioned above in the context of HIV) are
available. Safety aspects can first be assessed in clinical trials
outside of West Africa to circumvent political and logistical
problems in the endemic countries. We hope to see LASV vaccine
candidates moving into clinical trials within the next few years.
Clinical approval of a LASV vaccine would not only bring decades
of hard work to a successful end but would also justify the
resources (time and human resources, animal lives, and money)
that have been used.
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